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ABSTRACT The use of small molecules to interfere with protein-protein interactions has tremendous therapeutic appeal 
and is an area of intense interest. Numerous techniques exist to assess these interactions and their disruption. Many, 
however, require large amounts of protein, do not allow interactions to be followed in real time, are technically demand-
ing or require large capital expenditures and high levels of expertise. Surface plasmon resonance (SPR) represents a 
convenient alternative to these techniques with virtually none of their disadvantages. We have devised an SPR-based 
method that allows the heterodimeric association between the c-Myc (Myc) oncoprotein and its obligate partner Max to 
be quantified in a manner that agrees well with values obtained by other methods. We have adapted it to examine the 
ability of previously validated small molecules to interfere with Myc-Max heterodimerization and DNA binding. These 
inhibitors comprised two distinct classes of molecules that inhibit DNA binding by preventing Myc-Max interaction or 
distorting pre-formed heterodimers and rendering them incapable of DNA binding. Our studies also point out several 
potential artifacts and pitfalls to be considered when attempting to employ similar SPR-based methods. This technique 
should be readily adaptable to the study of other protein-protein interactions and their disruption by small molecules.
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INTRODUCTION
Protein-protein interactions are critical for virtually all cellular 
functions ranging from the transmission of growth factor signals to 
the assembly of multi-protein complexes and organelles [1,2]. Because 
abnormal protein-protein interactions are also causally implicated in 
numerous disease states [2,3], considerable effort has been devoted to 
the development of small molecules capable of blocking or reversing 
these associations and their pathological consequences [4,5]. Although 
some notable successes have been reported, significant challenges 
remain in achieving these goals [6].
We have focused on the development of small, drug-like compounds 
to prevent or disrupt the association between the c-Myc (Myc) oncop-
rotein transcription factor and its obligate partner Max, which interact 
via their respective basic helix loop helix-leucine zipper (bHLH-ZIP) 
dimerization domains [7-9]. De-regulated expression of Myc is im-
plicated in many different types of cancer [10] although even tumors 
without obvious Myc deregulation are dependent upon the oncoprotein 
for their proliferation and/or survival [11,12]. The Myc-Max heterod-
imer is required for the transcriptional regulation of numerous target 
genes whose encoded products determine most of the phenotypes that 
underlie the transformed state [13]. For these reasons, small molecules 
that directly interfere with Myc-Max dimerization (henceforth “Myc 
inhibitors”) present significant therapeutic potential [8,9].
Two mechanistically distinct classes of direct Myc inhibitors have 
been identified. The first, represented by the compounds 10058-F4 and 
10074-G5 and their analogs [14-19] bind to distinct regions of mono-
meric Myc’s intrinsically disordered bHLH-ZIP domain and create a 
localized distortion that prevents heterodimerization with Max [20,21]. 
Due to the high free energy of Myc-Max association, these compounds 
are much less able to promote the dissociation of pre-formed heterod-
imers [8,9]. Members of the second, and more recently recognized, 
class of direct Myc inhibitors, represented here by the synthetic α-helix 
mimetic JKY-2-169, interact poorly with individual Myc and Max 
proteins [22]. Rather, by virtue of being designed to recognize key 
arginine and hydrophobic residues within the distinct conformational 
spaces they occupy in the α-helical Myc-Max heterodimer, JKY-2-169 
distorts this structure, without causing its dissociation, and abrogates 
2 J Biol Methods  | 2015 | Vol. 2(2) | e18
POL Scientific
DNA binding [22] .
Various biophysical methods have been used to measure the effects 
of these small molecules on Myc-Max association or their binding to 
DNA. They include fluorescence polarization, electrophoretic mobil-
ity shift assays (EMSA), circular dichroism, and NMR spectroscopy 
[15,18,20,21]. While these methods are specific and variably quantitative, 
each is subject to factors that can compromise or restrict its use. These 
include the need for large amounts of purified proteins, the requirement 
that small molecules of interest be fluorescent and an inability in some 
cases to follow protein-protein or protein-DNA interactions in real time 
[8,9,23]. Techniques such as NMR spectroscopy also require substantial 
expertise and capital investments in appropriate instrumentation.
The Biacore™ biosensor, based on the surface plasmon resonance 
(SPR) detection principle, is an alternative method that permits the ac-
curate and quantitative assessment of protein-protein and protein-DNA 
interactions. In addition to requiring relatively low amounts of material, 
real-time, label-free kinetics of interactions including measurements 
of weak interactions between small molecules and proteins can be 
determined [24-27]. The ability to operate the Biacore in an automated 
manner also permits medium to high-throughput sample analysis. The 
Biacore is a mass-based detection system and changes in mass on the 
sensor chip surface as a result of the binding interaction are correlated 
to changes in the refractive index. This is reflected in the SPR signal, 
which may impose some challenges, particularly when the binding 
partner in solution possesses a low mass [28]. Present SPR technology 
has overcome this limitation to a great extent by introducing systems 
like the Biacore™ T200 and the Biacore™ 4000 which are routinely 
used in the analysis of small molecule drugs and inhibitors (100 Daltons 
or below) as well as fragment libraries.
We have previously used SPR to measure the interaction between 
10058-F4, 10074-G5 and a select group of their analogs with the bHLH-
ZIP domain of N-Myc, a close relative of c-Myc, whose over-expression 
is associated with advanced-stage, poor prognosis neuroblastomas 
[24,25]. The interaction of these small molecules with N-Myc correlated 
quite well with their ability to prevent the in situ formation of N-Myc-
Max heterodimers and to induce neuronal differentiation as previously 
described for 10058-F4 [24,26]. More recently, we have described an 
SPR-based method that allows for a more sensitive means of detecting 
the effects of these small molecules on Myc-Max heterodimer formation 
[24]. Rather than quantifying the direct interaction of the molecules with 
Myc, this alternative approach assesses their ability to prevent and/or 
disrupt the Myc-Max heterodimer’s binding to a biotinylated DNA target 
that is tethered to a streptavidin biosensor chip. The resultant loss of 
DNA binding is associated with a much more robust, reproducible and 
quantifiable signal. This technique also possesses greater versatility by 
virtue of its being amenable to the evaluation of compounds such as 
JKY-2-169 which induce non-DNA binding conformational distortions 
of the Myc-Max heterodimer without promoting its dissociation [22]. 
Although the methods described here are specifically aimed at assessing 
Myc inhibitors, they should be readily applicable to other protein-DNA 
interactions and their disruption with small molecules.
MATERIALS AND METHODS
Preparation of proteins
The bHLH-ZIP domain of human Myc (residues 353-437) along with 
full length Max(S) and Max(L) (151 and 160 residues, respectively, 
encoding the p20 and p21 isoforms, respectively) [7] were expressed 
in the pET151-D-TOPO vector as His6-N-terminally tagged fusion 
proteins in the E. coli strain BL21DE3(plysS) [15,20,21]. Bacterial 
cultures were grown at 37°C in L-Broth to an h ≈ 0.8 and then induced 
for 16 h with 1 mM isopropyl-L-thio-B-D-galactopyranoside (IPTG). 
Cultures were harvested, pelleted by centrifugation at 5,000 × g for 
10 min and lysed in a buffer containing 8 M urea; 100 mM NaH2PO4 
and 10 mM Tris-HCl, pH 8.0. Proteins were purified on an NTA nick-
el-agarose column (Qiagen, Inc., Valencia, CA) and eluted with a pH 
gradient according to the recommendations provided by the supplier. 
The purified proteins were then dialyzed against 150 mM NaCl, Tris-HCl 
pH 6.7 and cleaved with TEV protease at 25oC as previously described 
[20,27,28]. For larger amounts of protein, TEV protease:His6-tagged 
protein molar ratios were typically as low as 1:50 and were allowed 
to proceed for up to 72 h. The cleaved residues containing the His6 
tag were then removed by an additional round of NTA-nickel-agarose 
chromatography. The final preparations of Myc, Max(S) and Max(L) 
were dialyzed against HBS-EP running buffer (10 mM HEPES, pH 7.4; 
150 mM NaCl; 3 mM EDTA; 0.005% v/v Surfactant P20) and stored 
at -80°C in small aliquots.
Oligonucleotide synthesis
A biotin-tagged E-box-containing single-stranded oligonucleotide 
(5’-Biotin-TGAAGCAGAC CACGTGGTCGTCTTCA-3’, E-box 
sequence underlined) and its non-biotinylated complementary strand 
(both from IDT, Inc. Coralville, IA) were annealed at a 1:10 ratio in 
100 mM NaCl; 10 mM EDTA, pH 7.5 and 1 mM EDTA. The resultant 
double-stranded DNA (hereafter referred to as the oligonucleotide) was 
then diluted to 500 nM in high salt HBS-EP buffer (10 mM HEPES, 
pH 7.4; 500 mM NaCl; 3 mM EDTA; 0.005% v/v Surfactant P20).
SPR studies
All experiments were performed at 25°C using a Biacore™ 3000 
instrument and streptavadin-coated biosensor chips (SA-Chip GE 
Healthcare, Inc. Piscataway, NJ). All buffers were freshly prepared and 
filtered using bottle top or syringe filters (0.22 μm, Corning, Inc. Corning, 
NY) and de-gassed. The instrument was first primed three times with 
HBS-EP running buffer and flow cell 1 (FC1) was used as the reference 
flow cell, which was unmodified and lacked the oligonucleotide ligand. 
Flow cell 2 (FC2) was used for immobilization of the oligonucleotide. 
It was conditioned with three consecutive 1 min injections of 50 mM 
NaOH in 1 M NaCl, in accordance with the manufacturer’s instructions. 
The oligonucleotide was then injected over a 30 min period at a flow 
rate 10 ml /min followed by the Extraclean feature. Oligonucleotide 
immobilization levels of 700-800 RU were routinely observed under 
these conditions.
Protein-DNA binding assays were performed in HBS-EP running 
buffer at the relatively high flow rate of 60 ml/min to avoid or minimize 
any mass-transport limitation effects. Protein solutions ranging from 
3-100 nM were injected for 150 seconds followed by dissociation in 
running buffer for 100 seconds. At the end of the dissociation period the 
sensor chip was regenerated to remove any remaining bound material 
by injecting HBS-EP buffer containing 1 M NaCl and 0.002% SDS at 
30 ml/min for 30 seconds.
Myc inhibitor evaluations
Stock solutions (1 mM) of 10074-G5 and JKY-2-169 were prepared 
in 100% DMSO. All dilutions were performed in buffers containing 
5% DMSO. For protein binding studies, the compounds were pre-in-
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cubated for 30 min with monomeric Myc or Max(S) (20 nM each), 
with pre-formed Myc-Max(S) heterodimers (20 nM of each protein) 
or with Max(L) (40 nM). The mixture was then analyzed as described 
above for the protein-DNA binding assay except that the running buf-
fer contained 5% DMSO. A solvent correction curve was generated 
by adding varying amounts of DMSO to running buffer to generate a 
range of concentrations ranging from 4.5-5.8%.
Data analyses
 Data were analyzed with the BIA evaluation software 4.1 (GE 
Healthcare, Inc., Piscataway, NJ) using the 1:1 Langmuir model fit 
with mass transfer limitations for determination of the binding kinetics.
RESULTS AND DISCUSSION
 All experiments utilized His6-tagged recombinant Myc and Max 
proteins that were purified to near homogeneity using nickel-agarose 
affinity chromatography followed by cleavage of the His6 tag with 
TEV protease [15,20,21]. The final products were comprised only of 
endogenous sequences and were substantially free of other contaminat-
ing proteins (Fig. 1A). The Myc peptide consisted of the 84 residues 
comprising the bHLH-ZIP domain (amino acids 353-437) [15,20,21]. 
Two full-length isoforms of Max, termed Max(L) (160 residues) and 
Max(S) (151 residues), varying only by an N-terminal insertion of 9 
residues in the former protein, were used for different purposes [7]. In 
the absence of Myc, Max(L) forms a DNA-binding homodimer that 
serves as an excellent control to test the specificity of small molecule 
Myc inhibitors [14,15,19]. Like Max(L), Max(S) also forms low-affinity 
homodimers [29] but binds DNA poorly, if at all. It can therefore be 
used to unequivocally assess the DNA binding activity of high affinity 
Myc-Max heterodimers without interference or competition from other 
DNA binding species [14,15,30,31].
Figure 1. Characterization of purified proteins and quantification of their binding to DNA using SPR. A. SDS-PAGE of purified Myc and Max pro-
teins prior to or following cleavage of the His6 tags with TEV protease. 5 μg of each protein was resolved and stained with Coomassie Blue. B. Tethering 
of the oligonucleotide to the SA-Chip. C. After adjusting the relative response in (B) to 0, the indicated proteins were passed over the SA-Chip and their 
binding was assessed. Note that only Myc-Max(S) heterodimers and Max(L) homodimers were capable of binding the oligonucleotide as previously re-
ported [15,30,31]. D. Kinetic analysis of Myc-Max(S) binding to immobilized oligonucleotide. Equimolar concentrations of Myc and Max(S) were allowed 
to dimerize for 30 min at room temperature and then passed over the biosensor chip containing bound oligonucleotide. The raw data curves are shown 
in red and the fitted curves in grey . Note that in each case, these curves overlap, indicating a near perfect correlation between theoretically calculated 
binding and observed binding. E. Kinetics of Max(L) binding to the oligonucleotide was performed as described in (D).
Initial experiments attempting to detect Myc-Max(S) association 
by tethering His6-Myc to an NTA Biosensor chip and using Max(S) 
as the analyte were hindered by probable His6-Myc protein surface 
aggregation as evidenced by the inability of the protein to bind Max(S) 
or to be subsequently removed from the chip with high concentrations 
of nickel salts or urea. These findings are in keeping with the poor 
solubility of His6-Myc that necessitates its being maintained in dilute 
form following purification (HW, unpublished results). Indeed, even 
when such dilute solutions of Myc were used for attachment, eventual 
aggregation occurred due to the progressive accumulation of high local 
concentrations of protein on the chip surface. Reciprocal experiments, in 
which His6-Max(S) was bound to the chip surface and Myc was used as 
the analyte, allowed us to overcome this problem and demonstrate both 
time- and dose-dependent Myc-Max(S) heterodimerization (see below). 
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However, binding of a non-biotinylated double-stranded E-box-contain-
ing oligonucleotide to the resultant heterodimer was difficult to achieve, 
despite the ease with which it occurs in EMSA experiments [14-16]. We 
attribute this to probable steric hindrance arising from the proximity 
of the Myc and Max basic domains to the chip surface that precludes 
access to the oligonucleotide analyte. Additional interference with DNA 
binding under these conditions might arise as a result of conformation 
restraints imposed on the Myc bHLH-ZIP domain as a consequence of 
its surface attachment and/or to additional limitations to DNA binding 
arising from the proximity of the His6 tag to the basic domain.
More reproducible and robust results were obtained using an SA chip 
to which was attached a biotinylated, double-stranded E-box-containing 
oligonucleotide (hereafter referred to as the oligonucleotide) (Fig. 1B). 
As expected from previously published results [14,15,31], neither Myc 
nor Max(S) bound the oligonucleotide (Fig. 1C) whereas both Max(L) 
homodimers and Myc-Max heterodimers exhibited strong time- and 
dose-dependent binding (Fig. 1D and 1E). Additionally, in the absence 
of any proteins, the direct Myc inhibitors 10058-F4, 10074-G5 and 
JKY-2-169 [14,22] did not affect the response of the previously tethered 
oligonucleotide (data not shown). A 1:1 “Langmuir with Mass Transport” 
model, provided in the Biacore Evaluation software package and that 
takes into account the limitations of mass transfer, was used to fit the 
data to determine the binding kinetics. Because the actual percentage of 
Myc-Max(S) heterodimers in solution could not be directly determined, 
we relied on the association between Myc and a His6-tagged Max(S) 
protein that had been tethered to a nickel-impregnated biosensor chip 
(NTA Chip, Biacore, Inc). Testing serial two-fold dilutions of Myc on 
this chip allowed us to calculate a KD for Myc-Max(S) of ~6.08 nM 
(data not shown). Based on this value and using the equation: KD = 
[Myc]×[Max(S)]/[Myc-Max(S)], we calculated the true concentration of 
Myc-Max(S) heterodimers for each input concentration of their respective 
proteins and used these values to derive Figure 1D. This information 
allowed us to calculate DNA binding affinity for the Myc-Max(S) 
heterodimer using global fitting and we obtained a KD= 8.9 nM, which 
agreed well with a previous publication using independent means [32].
Figure 2. Differential effect of 10074-G5 and JKY-2-169 on oligonucleotide binding by Myc-Max(S). A. 10074-G5 prevents DNA binding by Myc-Max-
(S) heterodimers if added prior to their formation. 10074-G5 was pre-incubated with Myc for 30 min before the addition of Max(S). The entire mixture was 
then tested for DNA binding by passing over the SA-Chip containing the tethered oligonucleotide. B. 10074-G5 is much less effective at disrupting DNA 
binding by pre-formed Myc-Max(S) heterodimers. Pre-formed Myc-Max(S) heterodimers were incubated with the indicated concentrations of 10074-G5 
for 30 min and then passed over the SA-Chip as described in (A). C. 10074-G5 does not prevent DNA binding by Max(L) homodimers. D. The experiment 
described in A was repeated using JKY-2-169. E. The experiment described in B was repeated using JKY-2-169. F. The experiment described in C was 
repeated with JKY-2-169. For (B) and (E), change the label Myc-Max(S) to pre-formed Myc-Max(S) for clarification.
A similar calculation for the association of Max(L) homodimers 
with the oligonucleotide (Fig. 1E) could not be performed since the 
homodimers form spontaneously at the time of purification. However, 
even assuming the efficiency of this process to be 100%, the efficiency 
of DNA binding that we calculated was only about half that achieved 
by Myc-Max(S). The greater dependency of the KD for Myc-Max(S) 
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heterodimers on their absolute concentration likely reflects the ongoing 
competition of Max(S) to participate in both heterodimeric as well as 
homodimeric interactions. Taken together, these and the foregoing 
results indicate that the order of addition of the assay components, 
their conformation at the sensor chip surface and additional rotational 
limitations imposed by their attachment can exert major influences 
over the experimental outcome. Of lesser importance are the amounts 
of input protein whose dimerization variability can be minimized by 
employing the maximal achievable concentrations.
 Having identified conditions under which DNA binding by Myc-Max-
(S) and Max(L) could be reproducibly quantified, we next asked whether 
this could be prevented or reversed by two mechanistically distinct types 
of direct Myc inhibitors previously described by our group. An example 
of the first type of Myc inhibitor, 10074-G5, binds to a segment of Myc’s 
helix 1 domain lying immediately adjacent to the basic region [20,21]. 
The binding of 10074-G5 was confirmed by its ability to recognize an 
18 residue synthetic peptide encompassing this site with an affinity 
nearly equal to that obtained with the full-length bHLH-ZIP domain 
[20,21]. This interaction results in a local conformational distortion that 
interferes with the protein’s ability to interact with Max. The second 
type of Myc inhibitor, exemplified by the synthetic α-helix mimetic 
JKY-2-169, recognizes neither Myc monomers nor Max(L) homodi-
mers but instead alters the structure of the Myc-Max(S) heterodimer by 
interacting with arginine and hydrophobic residues located within the 
α-helical helix 1 domain in a manner that leads to loss of DNA binding 
but not heterodimerization [22].
When 10074-G5 was pre-incubated with Myc, exposed to Max(S) 
and then passed over the Biosensor chip, a dose-dependent reduction 
in DNA binding of the heterodimer was observed (Fig. 2A). In con-
trast, 10074-G5 was much less effective at reversing DNA binding 
by pre-formed Myc-Max(S) heterodimers (Fig. 2B). These results 
are consistent with the idea that compounds such as 10074-G5, while 
readily preventing Myc-Max interaction, are less efficient at disrupting 
pre-formed heterodimers due to their high free energy of association and 
the inherent difficulty in overcoming this with a small molecule [8,9]. 
That 10074-G5 also did not interfere with DNA binding by Max(L), 
a relatively low-affinity association (Fig. 2C) [29], is consistent with 
our previous results [14,20,21].
Our findings with 10074-G5 contrasted with those obtained with 
JKY-2-169 which promoted DNA-protein dissociation irrespective 
of whether it was added prior to or after Myc-Max(S) heterodimer 
formation (Fig. 2D and 2E). This molecule would be expected to 
bind to the Myc-Max(S) heterodimer immediately after its formation 
thereupon altering its structure and preventing its interaction with 
the oligonucleotide. We have previously used NMR spectroscopy to 
demonstrate the formation of such an altered structure following the 
addition of JKY-2-169 [22]. JKY-2-169 had much less of an effect on 
DNA binding by Max(L) homodimers (Fig. 2F), thus attesting to the 
specificity of the compound as previously noted and documented by both 
NMR spectroscopy and other methods [22]. Finally, although numerous 
factors can influence the cellular effects of Myc inhibitors [15,18], we 
would note that the results obtained with SPR were in good agreement 
with JKY-2-169 being a more potent inhibitor of Myc-over-expressing 
cancer cells than 10074-G5 [18,22].
The foregoing studies provide a relatively simple, rapid and quantita-
tive means of assessing DNA binding by Myc-Max(S) heterodimers and 
Max(L) homodimers in real-time. The method provides robust results 
that are in good agreement with those obtained by more traditional meth-
ods such as EMSAs or NMR [14,15,22] and that require much greater 
amounts of the protein reagents and/or highly specialized equipment 
and expertise. The method is also suitable for evaluating the capacity for 
Myc inhibitors to either prevent the formation of these dimeric proteins 
or disrupt pre-existing associations. It seems likely that this approach 
can be adapted to other types of protein-protein interactions and that 
the principles learned here will be applicable to these future studies.
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